FDA investigating PML case in Gilenya patient

FDA said it is investigating a case of progressive multifocal leukoencephalopathy (PML) that occurred in a multiple sclerosis (MS) patient in Italy who was receiving Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) for nearly eight months. Novartis first reported the case last month (see BioCentury Extra, July 30). ...